Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Meinian Ups Bid for Rival iKang Healthcare to $23.50/ADS

publication date: Dec 15, 2015
Meinian Onehealth Healthcare upped its bid for iKang Healthcare, a rival chain of China clinics, to $23.50 per ADS. Previously, Meinian offered $22 for each iKang ADS. iKang, which made a $17.80 bid per ADS to take the company private in late summer, has responded to Meinian's offer by proposing a poison pill that would make an outside takeover almost impossible. Its own privatization offer is now 32% below Meinian's, and so far iKang has not raised its original offer price. More details....

Stock Symbol: (NSDQ: KANG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital